Recent Press ReleasesApply01.14.2021Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults01.12.2021Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative01.08.2021An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission01.07.2021Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy01.05.2021Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference01.04.2021US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency12.29.2020Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®12.28.2020LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA12.28.2020Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health12.23.2020Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 VaccineMedia ContactsGet to Know UsCompany Fact SheetFeatured StoriesPodcastsPress Kits @Pfizer @Pfizer_Newsby pfizerTweets by pfizer_news
